News | News By Subject | News by Disease News By Date | Search News

Multiple myeloma News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
This Drug Could be Johnson & Johnson (JNJ)'s Next Billion-Dollar Blockbuster     1/30/2017
bluebird bio (BLUE), Celgene (CELG)'s Multiple Myeloma CAR-T Drug Shines in Tiny Study     12/2/2016
The History Between a Biogen (BIIB) Drug and a High-Profile Democratic Party Fundraiser     10/17/2016
Karyopharm (KPTI) Touts Mid-Stage Data, May See Quicker Approval of Multiple Myeloma Drug     9/6/2016
3 Biotechs Expecting to Release Clinical Trial Data Soon     9/1/2016
Genmab, Inc. (GEN.CO), Johnson & Johnson (JNJ)'s Daratumumab Granted Breakthrough Tag by the FDA     7/26/2016
Amgen (AMGN) Flinches Over Meeting to Review Cost of Multiple Myeloma Drugs     4/7/2016
Janssen Research & Development, Genentech (RHHBY) Forge Clinical Trials Agreement     3/23/2016
Three Drugs Could Catapult Three Big Pharma Revenues This Year     2/9/2016
FDA Grants Full Approval for Amgen (AMGN)'s Blood Cancer Drug     1/25/2016
FDA Approves Takeda (TKPYY)'s Ixazomib for Multiple Myeloma     11/20/2015
Johnson & Johnson (JNJ) Snags Early Approval for Breakthrough Multiple Myeloma Drug Darzalex     11/17/2015
FDA Declines to Approve Spectrum Pharma (SPPI)'s Evomela for Injection     10/23/2015
Three Cancer Drugs are Up for FDA Approval in October     9/28/2015
Karyopharm (KPTI) Tanks After Cancer Drug Trial Patients Get Sepsis     8/10/2015

News from Around the Web
Amgen (AMGN)’s Backup Plan For Kyprolis Flop     9/30/2016
American Society of Hematology: Secondary Cancers Cloud Myeloma Drug, Roswell Park Cancer Institute Study     12/10/2010
High Response Rates Seen In Phase-III Trial Of Chemotherapy, New Drug And Stem Cells In Myeloma, Azienda Ospedaliera Universitaria San Giovanni Battista of Torino Study     10/14/2010
Possible Genetic Links Between Environmental Toxins And Multiple Myeloma, Bank on a Cure(R) Study     8/14/2009
Treatment With Anti-anemia Drugs May Not Be Safe For Multiple Myeloma Patients, American Journal of Hematology     8/15/2008
One Gene May Be Key to Myeloma, National Cancer Institute Researchers Find     6/24/2008
Blocking a Single Protein Proves Toxic to Myeloma Cells in National Institutes of Health (NIH) Studies     6/23/2008
Three-Drug Combination "Extremely Promising" As First-Line Therapy for Multiple Myeloma, Researchers Say     12/14/2007
New Therapeutic Options for Newly Diagnosed Multiple Myeloma Patients     12/11/2007
Mayo Clinic: Multiple Myeloma Clinical Trial Shows Distinct Survival Benefit with Lower Dose of Steroids     12/10/2007
ZOLINZA (vorinostat) in Combination with Bortezomib Demonstrated Clinical Activity     12/10/2007
Gene Profiling Can Single Out the Worst Cases of Multiple Myeloma and Guide Therapy     9/19/2007
Emory University Researchers Identify Signaling Protein for Multiple Myeloma     9/11/2007
Potential Therapeutic Targets Identified in Multiple Myeloma     8/14/2007
Mayo Clinic Cancer Center Researcher Finds Mold By-product Kills Multiple Myeloma     4/16/2007

Press Releases
Celgene (CELG) Notified Of ANDA Filing For POMALYST     4/4/2017
Amgen (AMGN) Submits Applications In The US And Europe To Expand Current Indication For XGEVA (Denosumab) To Include Patients With Multiple Myeloma     4/4/2017
Amgen (AMGN) Submits Applications In The US And Europe To Expand Current Indication For XGEVA (denosumab) To Include Patients With Multiple Myeloma     4/4/2017
Sutro Biopharma ADC Targeting CD74 Eradicates B-Cell Hematologic Malignancy, Prolongs Survival In Tumor Models     4/3/2017
After Much Anticipation, Cellectar Biosciences  (CLRB) Initiates NCI-Supported Phase II Trial Of CLR 131 In Multiple Myeloma And Other Blood Cancers     3/30/2017
Aldevron Licenses Minicircle Technology To Support Collaboration With Myeloma Crowd And The Development Of Multiple Myeloma Treatments     3/29/2017
Oncolytics Biotech Inc. (ONC.TO) Enters Into First-In-Class Collaboration With Myeloma UK And Celgene (CELG) Using REOLYSIN In Combination With Imnovid Or Revlimid In Patients With Myeloma     3/16/2017
Amgen (AMGN) Presents New Data From Phase III XGEVA (Denosumab) Study In Multiple Myeloma Patients At The 16th International Myeloma Workshop     3/6/2017
Amgen (AMGN) Presents Overall Survival Data From KYPROLIS (carfilzomib) Phase III ENDEAVOR Trial At 16th International Myeloma Workshop     3/6/2017
GlycoMimetics, Inc. (GLYC) To Present New Preclinical Data In Multiple Myeloma At AACR Annual Meeting 2017     3/2/2017
SELLAS Life Sci Announces Updated Positive Phase II Data Reinforcing Meaningful Clinical Benefit Of Its WT1 Immunotherapeutic Anti-Cancer Treatment In Multiple Myeloma Patients     3/1/2017
Amgen (AMGN) Release: Phase III Head-To-Head Trial Showed KYPROLIS (Carfilzomib) Significantly Improved Overall Survival Compared To Velcade (Bortezomib) In Relapsed Or Refractory Multiple Myeloma Patients     2/28/2017
Cellectar Biosciences  (CLRB) Provides Phase I Trial Update Of CLR 131 In Multiple Myeloma: Median Progression-Free Survival Extends To 133 Days, Median Overall Survival Reaches 17.7 Months     2/27/2017
Janssen-Cilag AG Release: DARZALEX (Daratumumab) Receives Positive CHMP Opinion For The Treatment Of Multiple Myeloma In Patients Who Have Received At Least One Prior Therapy     2/24/2017
Celgene (CELG) Release: FDA Expands Indication For REVLIMID (Lenalidomide) As A Maintenance Treatment For Patients With Multiple Myeloma Following Autologous Hematopoietic Stem Cell Transplant (auto-HSCT)     2/23/2017

//-->